CKD: FDA approves expanded indication for ferric citrate

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The FDA has approved an expanded indication for ferric citrate tablets (Auryxia), allowing their use for the treatment of iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).

Why this matters